Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Eli Lilly & Co. : Lilly quarterly sales, profit beats forecasts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 02:01pm CET

Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products.

The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because Zyprexa's decline was not as steep as had been feared, said company spokesman Mark Taylor.

The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges.

Excluding special items, Lilly earned 92 cents per share. Analysts, on average, had expected 78 cents per share, according to Thomson Reuters I/B/E/S.

The company's shares rose 2.2 percent in premarket trading.

"Lilly just reported what looks like a solid first quarter," ISI Group analyst Mark Schoenebaum said in a research note.

But Schoenebaum predicted its shares would not react in a major way since investors are more focused on the company's progress in developing solanezumab, its experimental Alzheimer's disease treatment, than on quarterly earnings.

Data from the drug's late-stage trial is expected later this year. Although the drug is considered to be a long shot, investors say it would have huge sales potential if shown to slow progress of the memory-robbing disease, and speed Lilly's return to profit growth.

Global company revenue fell 4 percent to $5.6 billion, little affected by foreign exchange rates, above Wall Street expectations of $5.36 billion.

Sales of Zyprexa, which lost U.S. patent protection in October, tumbled 56 percent to $563 million, while Cymbalta sales jumped 23 percent to $1.11 billion.

Although Cymbalta's growth helped offset declines for Zyprexa in the quarter, the depression drug's own U.S. patent will lapse in mid-2013. Its sales will then shrink dramatically, worsening Lilly's long-feared patent cliff.

Global sales of Alimta, the company's lung cancer drug, rose 5 percent to $607 million. Its Humalog insulin rose 12 percent to $590 million, while its Humulin insulin brand grew 6 percent to $308 million.

The company slightly raised its 2012 profit forecast to between $3.15 and $3.30 per share, excluding special items. In January, Lilly forecast $3.10 to $3.20 per share, far below analyst estimates, sending the drugmaker's stock down sharply.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Maureen Bavdek)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND CO
02/27 ELI LILLY AND : Barriers to Integrated Care and How to Overcome Them
02/24 ELI LILLY AND : Trademark Application for "TOLIENT" Filed
02/24 ELI LILLY AND : New Enzymes and Coenzymes Data Have Been Reported by Researchers..
02/24 ELI LILLY AND : European Commission Approves Once-Daily Olumiant Tablets for Tre..
02/24 ELI LILLY AND : New Chronic Kidney Disease Findings Reported from E.B. Wang and ..
02/24 ELI LILLY AND : Additional results from pivotal RA-BEAM study published in New E..
02/22 ENDOCYTE : Appoints Michael T. Andriole as Chief Financial Officer
02/22 INSIDER TRADING ACTIVITY ELI LILLY A : LLY) – Major Shareholder Sold 230,0..
02/21 ELI LILLY AND : LILLY ELI & CO Management's Discussion and Analysis of Results o..
02/20 RELMADA THERAPEUTICS, INC. (OTCMKTS : RLMD) Files An 8-K Departure of Directors ..
More news
Sector news : Pharmaceuticals - NEC
08:35aDJASTRAZENECA : FDA OKs Once-Daily Qtern for Type-2 Diabetes
02/27DJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
02/27 FTSE ends higher on some positive earnings, insurers slip
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/27 Biotechs scorching today, IBB up 3%
02/24 Truxima Fires The Starting Gun In Biosimilar Race To The Bottom
02/24 4 COMPANIES WITH RECENT DIVIDEND INC : Review Using Dividend Safety Model - Febr..
02/24 European advisory committee positive actions
02/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2016 Update
Advertisement
Financials ($)
Sales 2017 22 136 M
EBIT 2017 5 494 M
Net income 2017 3 876 M
Debt 2017 4 117 M
Yield 2017 2,57%
P/E ratio 2017 25,43
P/E ratio 2018 21,19
EV / Sales 2017 4,33x
EV / Sales 2018 4,23x
Capitalization 91 644 M
More Financials
Chart ELI LILLY AND CO
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 86,5 $
Spread / Average Target 4,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Ricks President, Chief Executive Officer & Director
John C. Lechleiter Chairman
Derica W. Rice Chief Financial Officer & EVP-Global Services
Aarti Shah Chief Information Officer & Senior Vice President
Kathi P. Seifert Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO12.67%91 644
JOHNSON & JOHNSON6.53%332 993
ROCHE HOLDING LTD.5.42%209 283
PFIZER INC.5.48%204 030
NOVARTIS AG4.72%203 039
MERCK & CO., INC.12.38%181 558
More Results